EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

GLP-1-Rezeptoragonisten-Therapie und kardiorenale Outcomes bei Typ-1-Diabetes: Propensity-gematchte Real-World-Analyse

Anastasios Tentolouris iD, Charalampos Filippatos, Nikolaos-Iason Tepetes iD, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis iD, Kimon Stamatelopoulos, Theodosios Filippatos

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6347-6357

DOI: 10.1111/dom.70841 ↗

Auf einen Blick

Bei Erwachsenen mit Typ-1-Diabetes war eine GLP-1-basierte Therapie in dieser Real-World-Kohorte mit geringeren Risiken für Mortalität, Herzinsuffizienz, MACE, Hospitalisation und Hypoglykämie verbunden. Das DKA-Risiko war nicht erhöht.

Fragestellung

Welche kardiorenalen Wirksamkeits- und Sicherheitsoutcomes sind bei Erwachsenen mit Typ-1-Diabetes unter GLP-1-basierter Therapie im Vergleich ohne diese Therapie beobachtbar?

Methode

Retrospektive Kohortenstudie in TriNetX mit 1:1-Propensity-Matching; Ereignisse ab 6 Monaten nach Therapiebeginn; Vergleich von Erwachsenen mit Typ-1-Diabetes mit und ohne GLP-1-basierte Therapie.

Ergebnisse

Nach Matching waren 4088 Personen pro Gruppe eingeschlossen. Niedrigeres Risiko für Gesamtmortalität (HR 0,67; 95 %-KI 0,46–0,98), Herzinsuffizienz (HR 0,38; 95 %-KI 0,21–0,67), adaptierte MACE (HR 0,61; 95 %-KI 0,40–0,94), Hospitalisation (HR 0,70; 95 %-KI 0,51–0,96) und Hypoglykämie (HR 0,72; 95 %-KI 0,55–0,95).

Schlussfolgerung der Autor:innen

In dieser gematchten Real-World-Kohorte war GLP-1-basierte Therapie mit niedrigeren Risiken für mehrere klinische Outcomes und ohne erhöhtes DKA-Risiko assoziiert. Randomisierte kontrollierte Studien sind zur Bestätigung erforderlich.

Kernaussagen

  • Gesamtmortalität, HF, MACE und Hospitalisation waren seltener unter GLP-1-Therapie.
  • Hypoglykämie war unter GLP-1-Therapie seltener; DKA nahm nicht zu.
  • Myokardinfarkt, ischämischer Schlaganfall und CKD unterschieden sich nicht signifikant.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Journal article in Diabetes, Obesity and Metabolism, published online on 2026-05-06. Written by Anastasios Tentolouris and 7 co-authors. Institution: First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, Laiko General Hospital, National and Kapodistrian Univers…. Major MEDLINE topics: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Cardiovascular Diseases. Cited 4 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort. Materials and Methods This retrospective cohort study utilised the TriNetX global health research network. Adults with T1D were classified by exposure to GLP‐1‐based therapies. Propensity score matching (1:1) balanced baseline characteristics for age, sex, demographic characteristics, cardiometabolic risk factors, comorbidities, medication use, and laboratory parameters including lipid profile and glycemic control. Outcomes included all‐cause mortality, myocardial infarction, cerebral infarction, heart failure (HF), adapted major adverse cardiovascular events (MACE—all CV clinical outcomes), chronic kidney disease (CKD), and all‐cause hospitalisation, plus safety outcomes (hypoglycemia and DKA). Event accrual began 6 months after therapy initiation.

Results

After matching, 4088 individuals per group were included. GLP‐1‐based therapy was associated with lower risks of all‐cause mortality (HR 0.67, 95% CI 0.46–0.98), HF (HR 0.38, 95% CI 0.21–0.67), adapted‐MACE (HR 0.61, 95% CI 0.40–0.94) and all‐cause hospitalisation (HR 0.70, 95% CI 0.51–0.96). No significant differences were observed for myocardial infarction, ischemic stroke, or CKD. DKA incidence was not increased, while hypoglycemia risk was lower with GLP‐1 therapy (HR 0.72, 95% CI 0.55–0.95). Less than 10 (0.2%) events of pancreatitis were noted in both groups.

Conclusions

In this propensity score‐matched real‐world cohort of adults with T1D, GLP‐1‐based therapy was associated with lower risks of all‐cause mortality, HF, adapted‐MACE, hospitalisation, and hypoglycemia without increased DKA risk. Randomised controlled trials are needed to confirm these findings.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsCardiovascular DiseasesHumansFemaleMaleRetrospective StudiesPropensity ScoreAdultMiddle AgedHypoglycemiaDiabetic KetoacidosisTreatment OutcomeHeart FailureRenal Insufficiency, Chronic

Author keywords

GLP‐1 receptor agonistscardiovascular outcomesheart failurehospitalisationkidney outcomesmortalitypropensity score matchingtirzepatidetype 1 diabetes

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Authors and institutions

  • First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Internal Medicine, School of Medicine, University of Crete, Crete, Greece.

ORCID profiles: Anastasios Tentolouris, Nikolaos-Iason Tepetes, Alexandros Briasoulis

Cite

APA

Tentolouris, A., Filippatos, C., Tepetes, N. I., Gavriatopoulou, M., Terpos, E., Briasoulis, A., Stamatelopoulos, K., & Filippatos, T. (2026). GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis. Diabetes, Obesity and Metabolism, 28(7), 6347-6357. https://doi.org/10.1111/dom.70841

Vancouver

Tentolouris A, Filippatos C, Tepetes NI, Gavriatopoulou M, Terpos E, Briasoulis A, et al. GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis. Diabetes, Obesity and Metabolism. 2026;28(7):6347-6357. doi:10.1111/dom.70841

BibTeX
@article{Tentolouris2026,
  author = {Tentolouris, Anastasios and Filippatos, Charalampos and Tepetes, Nikolaos-Iason and Gavriatopoulou, Maria and Terpos, Evangelos and Briasoulis, Alexandros and Stamatelopoulos, Kimon and Filippatos, Theodosios},
  title = {GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6347--6357},
  doi = {10.1111/dom.70841}
}
Start for free →